Company Interview / Imricor makes cardiac ablation faster, safer, and smarter

Imricor (ASX:IMR) is focused on revolutionising interventional cardiac procedures by using real-time MRI guidance to improve safety and effectiveness. Nick Corkill highlights the vast potential of the cardiac catheter ablation market, which addresses arrhythmias affecting up to one in four people over 74. Corkill states the market was valued at $12 billion last year and predicts it may exceed $30 billion within the next decade. Imricor has spent twenty years developing a comprehensive suite of MRI-compatible devices, now fully approved in Europe and progressing through US regulatory processes, with commercialisation underway in Europe and the Middle East.

Corkill outlines a strong competitive position for Imricor as the only company offering MRI-guided ablation devices, noting that major players all rely on legacy X-ray technology. The MRI approach not only provides superior soft tissue imaging without radiation but also reduces costs, enhances efficiency for hospitals, and lowers risk for doctors. The recurring revenue per hospital is estimated at around $3 million, and the company reports a strengthening sales pipeline as market awareness builds.

Imricor’s partnership with MRI manufacturers Siemens, Philips, and GE creates significant barriers for competitor entry. Corkill expresses optimism for accelerated growth as regulatory hurdles ease and the company scales globally, offering a compelling proposition for patients, hospitals, and insurers alike.

You should be aware that companies presenting do so under commercial agreement with AUSBIZ CAPITAL PTY LTD